Loading
companiesCompany
MedPacto
MedPacto is a South Korean biotech whose oral TGF-beta receptor inhibitor vactosertib is being tested with chemotherapy and checkpoint inhibitors in colorectal, stomach and bone-marrow cancers.
Also called: MedPacto Inc.메드팩토KOSDAQ:235980
Overview
MedPacto, listed on KOSDAQ, develops vactosertib (TEW-7197), an oral inhibitor of the TGF-beta type 1 receptor kinase ALK5 that aims to relieve the immunosuppressive and fibrotic effects of TGF-beta in the tumour microenvironment. Vactosertib is in a phase 2/3 trial with FOLFIRI and bevacizumab in second-line metastatic colorectal cancer and has been studied with pembrolizumab in colorectal and gastric cancer, with pomalidomide in multiple myeloma and in osteosarcoma.
Headquarters
Seoul, KR
Scorecard
All companies#381of 1244 companies, score 10
- phase 1/2 +1
- modalities +2
- registry trials +7
0 approved, 0 in phase 3, 1 earlier, 0 targets, 14 registry studies. Formula on the scorecards page.
Type
Biotech · KOSDAQ:235980
Stage
Public
Website
Phase 2Oral serine/threonine kinase inhibitor
Vactosertib is an oral serine/threonine kinase inhibitor from MedPacto, Inc., in registered phase 2 trials for osteosarcoma.
drugs
Phase 2Oral serine/threonine kinase inhibitor